Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiersRecognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS
Kaitlin Batley, MD
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiersIdentifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP
Bethany Lussier, MD
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
On the Frontlines of Familial Chylomicronemia SyndromeCardiometabolic Considerations in Familial Chylomicronemia Syndrome
Steve Jackson, PharmD
Robert H. Eckel, MD, FAHA, FACC, FNLA
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP
Petros Grivas, MD, PhD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Project Oncology®ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Charles Turck, PharmD, BCPS, BCCCP
Guru P. Sonpavde, MD
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
- advertisement
Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
CME/CEFuture-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
Marc A. Riedl, MD, MS
Treatment of a Broader Population of Patients With DMD
CME/CETreatment of a Broader Population of Patients With DMD
Crystal Proud, MD
Erika Finanger, MD, MS
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
MinuteCE®Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
CASR and ADH1: Integrating Biology and Genetic Screening
MinuteCE®CASR and ADH1: Integrating Biology and Genetic Screening
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Therapeutic Options for ADH1 and Hypoparathyroidism
MinuteCE®Therapeutic Options for ADH1 and Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
- advertisement
- 05/14/2026
- 05/01/2026
- 05/01/2026
- 04/30/2026
- 04/28/2026
- 04/27/2026